Drug Pricing
Expert articles and analysis related to drug pricing.
AI Summary — Last 7 Days
The Trump administration is moving drug-pricing policy into Medicaid through the GENEROUS / most-favored-nation framework, with President Trump saying all 50 states, D.C., and Puerto Rico will participate, while reporting indicates CMS is also offering manufacturers exemptions from Medicare pricing demonstrations such as Globe and Guard if they provide additional Medicaid rebates (Endpoints, Endpoints). For VBC stakeholders, the key dynamic is a shift from isolated Medicare drug demonstrations toward cross-program rebate leverage, creating new uncertainty for Medicaid managed care rates, state supplemental rebate strategy, formulary access, and total-cost-of-care benchmarks. At the same time, oncology stakeholders are pressing CMS to ensure 2027 hospital outpatient reimbursement updates protect cancer care, underscoring the tension between drug-spend savings and maintaining access to high-cost specialty therapies in value-based oncology and ACO-aligned care models.
Related Articles
All 50 states sign up for most favored nation prices under Medicaid, Trump says
President Donald Trump on Friday announced that all 50 states, Washington, DC, and Puerto Rico will participate in a new drug pricing model under which pharma companies will provide supplemental rebat...
White House Extends MFN Pricing to Every State Medicaid Program
Internal CMS email confirms Globe and Guard exemption plan
The Centers for Medicare and Medicaid Services has exempted drugmakers from two pricing demonstration programs in Medicare if they agree to provide additional rebates in Medicaid, according to interna...
Klomp, Warren spar over MFN deal contracts
Top HHS official Chris Klomp had a relatively mild nomination hearing with senators on Tuesday, but he sparred with Sen. Elizabeth Warren (D-MA) over voluntary agreements with large drugmakers and wha...
J&J adds 340B claims data requirements amid growing manufacturer restrictions
Johnson & Johnson joined the list of drug manufacturers requiring providers to submit claims data on in-house pharmacy drugs as a condition of receiving discounts in the 340B Drug Pricing Program. Hos...
Comparison of Recent 340B Bills
Comparison of Recent 340B Bills American Hospital Association
Medicare's new drug pricing plan could backfire, driving up prices worldwide, study warns
The US experiments with international reference pricing for prescription drugs
The US experiments with international reference pricing for prescription drugs The Lancet
The US experiments with international reference pricing for prescription drugs
The US experiments with international reference pricing for prescription drugs The Lancet
Most-favoured-nation pricing for prescription drugs in US Medicare: a cohort study
Most-favoured-nation pricing for prescription drugs in US Medicare: a cohort study The Lancet